A Preventive Behavioral Intervention for Young Adults With Psychotic Experiences
Launched by MASSACHUSETTS GENERAL HOSPITAL · Apr 14, 2025
Trial Information
Current as of July 23, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at a program called Resilience Training, aimed at helping college students who may be at risk for developing serious mental health issues, such as psychotic disorders, mood disorders, or anxiety disorders. The study is open to young adults aged 18 to 30 who are in their first or second year of college and have reported experiencing some psychotic symptoms. Participants will be randomly assigned to either receive the Resilience Training or not, to see if this program can help prevent the development of more serious mental health conditions.
To participate, students must be enrolled at the college where the trial is taking place and have a score on a specific questionnaire that indicates they are at risk. However, those who are currently receiving treatment for mental health issues, taking certain medications, or have more severe mental health diagnoses won't be eligible. If you join the study, you can expect to learn skills that may help improve your mental well-being, and you'll be contributing to important research that could help others in the future.
Gender
ALL
Eligibility criteria
- Inclusion criteria:
- • 1. 18-30 years old
- • 2. Enrolled as a first or second year student (i.e., freshman or sophomore) in an undergraduate program at the college or university where the intervention takes place
- • 3. Students who endorse some psychotic experiences (Peter's et al. Delusion Inventory (PDI) score \> 3)
- Exclusion criteria:
- • 1. Inability to provide informed consent
- • 2. Not proficient in English
- • 3. Current self-reported Diagnostic Statistical Manual 5 (DSM-5) diagnosis with active symptoms (such as active psychotic symptoms, current suicidality, serious active alcohol or substance use, marked deterioration in functioning over the prior month) determined by clinical interview with participant, or self-report of a psychiatric diagnosis that necessitates close monitoring or individual therapy and/or inpatient or partial hospitalization
- • 4. Current enrollment in psychological or behavioral health treatment.
- • 5. Current use of psychotropic medications (other than stimulants) prescribed by a physician.
- • 6. A diagnosis of a serious, chronic mental illness as determined by the Mini-International Neuropsychiatric Interview (MINI)
About Massachusetts General Hospital
Massachusetts General Hospital (MGH) is a leading academic medical center located in Boston, Massachusetts, renowned for its commitment to advancing medical research and patient care. As a prominent teaching hospital affiliated with Harvard Medical School, MGH plays a pivotal role in clinical trials across a wide range of disciplines, including cardiology, oncology, neurology, and more. The institution is dedicated to fostering innovative research that translates into effective therapies and improved health outcomes. MGH's Clinical Trials Office provides comprehensive support to facilitate the design, implementation, and management of clinical studies, ensuring adherence to the highest ethical standards and regulatory compliance. With a focus on collaboration and patient-centered care, MGH strives to enhance medical knowledge and contribute to the future of healthcare.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Charlestown, Massachusetts, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported